Nature Communications (Nov 2020)

Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer

  • Birendra Kumar Sah,
  • Benyan Zhang,
  • Huan Zhang,
  • Jian Li,
  • Fei Yuan,
  • Tao Ma,
  • Min Shi,
  • Wei Xu,
  • Zhenglun Zhu,
  • Wentao Liu,
  • Chao Yan,
  • Chen Li,
  • Bingya Liu,
  • Min Yan,
  • Zhenggang Zhu

DOI
https://doi.org/10.1038/s41467-020-19965-6
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 8

Abstract

Read online

Neoadjuvant FLOT regimen has shown promising results for the treatment of locally advanced gastric cancer, however SOX regimen remains the preferred chemotherapy in Eastern countries. Here the authors report that the two therapies result in similar outcomes, measured as clinical downstaging and pathological response, in a phase II randomized clinical trial.